- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
- Phase 4
Thyroid Carcinomais the most common malignant tumor of endocrine system. Most frequent type of thyroid malignancy is papillary carcinoma. These tumors frequently have genetic alterations leading to activation of mitogen-activated protein kinase (MAPK) signaling pathway. Thyroid carcinoma manifests as a palpable, painless solitary thyroid nodule. Symptoms associated with thyroid carcinoma are solitary nodules, hard and fixed nodules, neck pain, cough, breathing problem, trouble swallowing, voice changes etc. Thyroid carcinoma diagnosis includes blood test, fine needle aspiration biopsy, CT scan, Ultrasonography, MRI, Indirect laryngoscopy, PET Scan, Nuclear medicine scan, etc. Generally, treatment of thyroid cancers includes chemotherapy, hormone therapy, radiation therapy, surgery, targeted therapy.
Key Developments:
- In March 2017, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.commenced an open Label Phase ? Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
- In November 2015, Kolltan Pharmaceuticals, Inc., presented pre-clinical findings which determines that Company’s KTN3379 reverses ErbB3-mediated resistance of BARF and MEK inhibitors in BRAF-mutated thyroid cancer and melanoma. Based on these pre-clinical findings support Kolltan’s ongoing Phase 1b clinical trials in BRAF-mutant tumors and the recently initiated clinical trial in thyroid cancer. In November 2016, Celldex Therapeutics, Inc. acquired Kolltan Pharmaceuticals. Kolltens KTN3379 has changed to CDX_3379.
Thyroid Carcinoma Disease Pipeline Drugs Assessment Dynamics
Thyroid CarcinomaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Thyroid Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Thyroid Carcinoma disease pipeline drugs development. This report studies the dynamics of the Thyroid Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Thyroid Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Thyroid Carcinomadisease Pipeline Drugs Assessment Segmentation
By Trial Phase
By Drugs
- Pembrolizumab
- Nivolumab
- Sorafenib
- Sulfatinib
- Anlotinib
- Nab-paclitaxel
- Pazopanib Hydrochloride
- Others
By Types of Thyroid Cancer
- Papillary Carcinoma
- Follicular Carcinoma
- Hurthle Cell Carcinoma
- Medullary Thyroid Carcinoma
- Anaplastic Carcinoma
By Route of Administration
- Oral
- Parenteral
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Trial Phase |
| 2.2.2. Drugs |
| 2.2.3.Types of Thyroid Cancer |
| 2.2.4.Route of Administration |
| 3. Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market By Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Preclinical Trials |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Phase 1 |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Phase 2 |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Phase 3 |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Phase 4 |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market By Drugs, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Pembrolizumab |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Nivolumab |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Sorafenib |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Sulfatinib |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Anlotinib |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Nab-paclitaxel |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Pazopanib Hydrochloride |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Others |
| 6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 7. Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market By Types of Thyroid Cancer, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Papillary Carcinoma |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Follicular Carcinoma |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Hurthle Cell Carcinoma |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Medullary Thyroid Carcinoma |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Anaplastic Carcinoma |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Thyroid Carcinomadisease Pipeline Drugs Assessment Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Oral |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Parenteral |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9. Competition Landscape |
| 9.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 9.2.1.Eisai Inc. |
| 9.2.2.Pfizer |
| 9.2.3.Astra Zeneca |
| 9.2.4.GlaxoSmithKline |
| 9.2.5.Novartis Pharmaceuticals |
| 9.2.6.Bayer |
| 9.2.7.Sanofi |
| 9.2.8.Celldex Therapeutics |
| 9.2.9.Genentech, Inc. |
| 10. Research Methodology |
| 11. Appendix and Abbreviations |
- Eisai Inc.
- Pfizer
- Astra Zeneca
- GlaxoSmithKline
- Novartis Pharmaceuticals
- Bayer
- Sanofi
- Celldex Therapeutics
- Genentech, Inc.